Abstract:Immunostimulatory therapies based on pattern recognition receptors (PRRs) have emerged as an effective approach in the fight against cancer, with the ability to recruit tumor-specific lymphocytes in a low-immunogenicity tumor environment. The agonist cyclic dinucleotides (CDNs) of the stimulator of interferon gene (STING) are a group of very promising anticancer molecules that increase tumor immunogenicity by activating innate immunity. However, the tumor immune efficacy of CDNs is limited by several factors, including relatively narrow cytokine production, inefficient delivery to STING, and rapid clearance. In addition, a single adjuvant molecule is unable to elicit a broad cytokine response and thus cannot further amplify the anticancer effect. To address this problem, two or more agonist molecules are often used together to synergistically enhance immune efficacy. In this work, we found that a combination of the STING agonist CDGSF and the Toll-like receptor 7/8 (TLR7/8) agonist 522 produced a broader cytokine response. Subsequently, we developed multicomponent nanovaccines (MCNVs) consisting of a PC7A polymer as a nanocarrier encapsulating the antigen OVA and adjuvant molecules. These MCNVs activate bone marrow-derived dendritic cells (BMDCs) to produce multiple proinflammatory factors that promote antigen cross-presentation to stimulate specific antitumor T-cell responses. In in vivo experiments, we observed that MCNVs triggered a strong T-cell response in tumor-infiltrating lymphocytes, resulting in significant tumor regression and, notably, a 100% survival rate in mice through 25 days without other partnering therapies. These data suggest that our nanovaccines have great potential to advance cancer immunotherapy with increased durability and potency.

Lanthanide-Nucleotide Coordination Nanoparticles for STING Activation

Self-Assembled STING-Activating Coordination Nanoparticles for Cancer Immunotherapy and Vaccine Applications

Supramolecular Cyclic Dinucleotide Nanoparticles for STING-Mediated Cancer Immunotherapy

Design and syntheses of a bimolecular STING agonist based on the covalent STING antagonist

Tumor-responsive Covalent Organic Polymeric Nanoparticles Enhancing STING Activation for Cancer Immunotherapy

Discovery of Novel Thieno[2,3-d]imidazole Derivatives As Agonists of Human STING for Antitumor Immunotherapy Using Systemic Administration.

Nanoparticle‐Mediated STING Activation for Cancer Immunotherapy

Nanomaterial-encapsulated STING agonists for immune modulation in cancer therapy

Advanced nanomaterials targeting activation of STING for enhanced cancer immunotherapy

Structure−Activity Relationship Study of Benzothiophene Oxobutanoic Acid Analogues Leading to Novel Stimulator of Interferon Gene (STING) Agonists

2',4'‐LNA‐Functionalized 5′‐S‐phosphorothioester CDNs as STING agonist

An Immunocompetent Hafnium Oxide-Based STING Nanoagonist for Cancer Radio-immunotherapy

Novel Emerging Nano-Assisted Anti-Cancer Strategies Based on the STING Pathway

Design, Synthesis and Biological Evaluation of (2′,5′ and 3′5′-Linked) cGAMP Analogs that Activate Stimulator of Interferon Genes (STING)

Nanoformulations of Chemotherapeutic Activators for cGAS-STING Pathway in Tumor Chemoimmunotherapy

In situ activation of STING pathway with polymeric SN38 for cancer chemoimmunotherapy

Apoptotic Body-Mediated Intracellular Delivery Strategy for Enhanced STING Activation and Improved Tumor Immunogenicity

Investigation of the enhanced antitumour potency of STING agonist after conjugation to polymer nanoparticles

Nano-STING agonist-decorated microrobots boost innate and adaptive anti-tumor immunity

Activating Innate Immunity by a STING Signal Amplifier for Local and Systemic Immunotherapy

STING and TLR7/8 agonists-based nanovaccines for synergistic antitumor immune activation